Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited has informed the Exchange about Schedule of meet for Investors' Meet under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited has received an ESG rating of 70 from NSE Sustainability Ratings and Analytics Limited.

Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited has informed the Exchange about the completion of dispatch of Postal Ballot Notice through electronic mode to its members whose email IDs are registered with the company/depositories as on July 31, 2026.

Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited has informed the Exchange regarding Notice of Postal Ballot for the appointment of Shanti Ekambaram as an Independent Director of the Company.

Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited has informed the Exchange about the transcript of a conference call with analysts/investors on financial results for the quarter ended 30th June, 2026, which is available on the company's website.

Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited has informed the Exchange regarding Change in Director(s) of the company, specifically the cessation of Ameera Shah as an Independent Director due to completion of her term.

Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited has informed the Exchange about the link of the recording of the conference call with analysts/investors on financial results for the quarter ended 30th June, 2026, which is available on the company's website.

Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited has informed the Exchange about change in Management, with Hasmukh Patel, Sushil Jaiswal, and Sunil Nadkarni ceasing to be part of Senior Management due to change in reporting structure, effective July 30, 2026.

Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 30, 2026, titled 'A Press Release on Financial Results which is being submitted to the media is also enclosed herewith as an Annexure B.' The company has approved its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, and will publish an extract of the unaudited consolidated financial results. Ameera Shah will be completing her term as an Independent Director of the Company on August 1, 2026.

Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited has announced its unaudited financial results for the quarter ended 30-Jun-26, with the Board approving the results and a limited review report by BS R & Co. LLP. The company also announced that Ameera Shah will be completing her term as an Independent Director on 01-Aug-26.

Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited has appointed Shanti Ekambaram as an Additional Independent Director of the company, effective July 30, 2026, for a term of 3 consecutive years, subject to shareholder approval.

Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited has received final listing and trading approval for 4,19,22,416 new equity shares issued under the scheme of amalgamation with J. B. Chemicals & Pharmaceuticals Limited.

Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited has informed the Exchange about General Updates - Allotment of 4,19,22,416 fully paid-up Equity shares of the Company to the eligible shareholders of J. B. Chemicals & Pharmaceuticals Limited as on the Record Date i.e. 17th July, 2026, in terms Scheme of Amalgamation of J. B. Chemicals & Pharmaceuticals Limited with Torrent Pharmaceuticals Limited and their respective shareholders.

Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited has informed the Exchange about the dissolution of its wholly owned subsidiary, Curatio Inc., Philippines, with effect from July 10, 2026. The company has received communication of the dissolution on July 17, 2026, and has provided details as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited has informed the Exchange about General Updates, specifically that Crisil ESG Ratings & Analytics Limited has independently assigned the rating of 'Crisil ESG 66' and the Core ESG rating of 'Crisil Core ESG 74'.

Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited has scheduled a teleconference with investors and analysts on July 30, 2026, to discuss the financial performance for the quarter ended June 30, 2026.

Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited is implementing a voluntary recall of select batches of Semalix injection disposable pens as a precautionary measure due to a product recall notification from its manufacturer Dr. Reddy's Laboratories Ltd.

Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited has informed the Exchange about a special window for transfer and dematerialization requests of physical shares, as published in the Financial Express newspaper.

Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited has informed the Exchange regarding the Amendment to AOA/MOA of the company, following the Scheme of Amalgamation of J. B. Chemicals & Pharmaceuticals Limited with Torrent Pharmaceuticals Limited, which has become effective on 8th July, 2026.

Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited has informed the Exchange about the effectiveness of the Scheme of Amalgamation of J. B. Chemicals & Pharmaceuticals Limited with Torrent Pharmaceuticals Limited, as approved by the Hon'ble National Company Law Tribunal, Ahmedabad Bench.